SITAVIG (acyclovir) buccal pill is applied locally to the gum and releases medication because the buccal tablet step by step dissolves. medication may be a artificial purine glycoside analogue active against herpes viruses.
Acyclovir drug substance may be a white or nearly white crystalline powder. SITAVIG contains fifty mg of medication, USP and also the following inactive ingredients: hypromellose, USP; milk supermolecule concentrate; metallic element lauryl sulphate, NF; Mg stearate, NF; crystalline polyose, NF; povidone, USP; mixture silicon oxide, NF.
Generic Name: acyclovir buccal tablets
SITAVIG is indicated for the treatment of repeated cold sore (cold sores) in immunocompetent adults.
One SITAVIG fifty mg buccal pill ought to be applied as one dose to the higher gum region (canine fossa).
SITAVIG ought to be applied among one hour once the onset of symptom symptoms and before the looks of any signs of fever blister lesions. The pill ought to be applied with a dry finger directly once taking it out of the blister. The pill ought to be placed to the higher gum simply on top of the tooth tooth (canine fossa) and control in situ with a small pressure over the upper lip for thirty seconds to make sure adhesion.
For comfort the rounded aspect ought to be placed to the higher gum, however either aspect of the pill may be applied. pill ought to be applied on the identical aspect of the mouth because the fever blister symptoms.
SITAVIG shouldn't be crushed, chewed, sucked or enclosed.
Food and drink may be taken ordinarily once SITAVIG is in situ. Avoid any scenario which can interfere with adhesion of the pill like manduction gum, touching or pressing the pill once placement, carrying higher dental appliance, and brushing teeth. If the teeth have to be cleansed whereas the pill is in situ, rinse the mouth gently. Drink many liquids within the case of xerostomia.
Sitavig Side Effects:
adverse reaction rates determined within the clinical trials of a drug can not be directly compared to rates in the clinical trials of another drug and should not mirror the rates observed in clinical follow.
The overall safety of SITAVIG was assessed in 378 adult subjects having a minimum of four cold sore episodes the previous year.
One irregular, double-blind, placebo controled trial was conducted in patients with perennial cold sore (cold sores). during this trial, 378 HSV infected subjects used SITAVIG as one dose, and 397 subjects used placebo.
The treatment nascent adverse events thought-about associated with the treatment that occurred in bigger than or capable one hundred forty five of patients enclosed headache (1% SITAVIG vs. two placebo) and application web site pain (1% each arms). There was no discontinuance of SITAVIG because of adverse drug reactions. Most treatment associated with adverse events were delicate or moderate in severity. One report of headache from each treatment arms was classified as severe.